C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV

Adam J Nelson,Rishi Puri,Danielle M Brennan,Todd J Anderson,Leslie Cho,Christie M Ballantyne,John Jp Kastelein,Wolfgang Koenig,Helina Kassahun,Ransi M Somaratne,Scott M Wasserman,Steven E Nissen,Stephen J Nicholls

American Journal of Preventive Cardiology（2020）

引用 2|浏览1

暂无评分

摘要

The ability of evolocumab to induce regression in statin-treated patients is not attenuated by the presence of enhanced systemic inflammation. This underscores the potential benefits of intensive lipid lowering, even in the presence of heightened inflammatory states.

查看译文

关键词

PCSK9 inhibitor,Atherosclerosis,C-reactive protein,Intravascular imaging,IVUS

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要